Market Cap 123.53M
Revenue (ttm) 4.06M
Net Income (ttm) -50.22M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,236.95%
Debt to Equity Ratio 0.00
Volume 200,000
Avg Vol 216,464
Day's Range N/A - N/A
Shares Out 32.17M
Stochastic %K 94%
Beta 1.52
Analysts Sell
Price Target $8.33

Company Profile

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The compa...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 949 409 7600
Website: imdxinc.com
Address:
2 International Plaza Dr., Suite 510, Nashville, United States
JohnPDaly
JohnPDaly Apr. 21 at 11:43 AM
0 · Reply
JohnPDaly
JohnPDaly Apr. 21 at 11:14 AM
$IMDX Daddy is home.
0 · Reply
SocioCobb
SocioCobb Apr. 21 at 4:54 AM
0 · Reply
JohnPDaly
JohnPDaly Apr. 21 at 2:28 AM
SEC-Outline $IMDX https://otp.tools.investis.com/clients/us/oncocyte/SEC/sec-outline.aspx?FilingId=19354433&Cik=0001642380&PaperOnly=0&HasOriginal=1
0 · Reply
jackedmund99
jackedmund99 Apr. 20 at 11:49 PM
$IMDX Neil Bradshaw, and Broadwood partners just bought more stock
0 · Reply
VaporWaves
VaporWaves Apr. 20 at 1:35 AM
$IMDX FDA Submission: On March 26, 2026, the company officially submitted GraftAssureDx for FDA review. This is an in-vitro diagnostic (IVD) test kit designed to monitor kidney transplant rejection using donor-derived cell-free DNA
0 · Reply
jackedmund99
jackedmund99 Apr. 17 at 3:25 PM
$IMDX create a weakness in the Stock so they can steal more shares cause they know what’s about to happen. The Stock is getting ready to be a teenager. It’s gonna have huge sales and there’s no real competition right now. I’m buying —thank you
1 · Reply
Bogwood
Bogwood Apr. 15 at 9:36 PM
$IMDX writing's on the wall that GraftAssure works from $CDNA's corp dev update today. Again, CareDx, EuroBio, Eurofins, TMO/Devyser and Natera are all checkmated because NGS takes too long to process even if performed in-house. The only competitors that could compete in theory would be Werfen/Omixon, but they aren't even close to setting up their FDA trial
1 · Reply
StockScanners
StockScanners Apr. 15 at 3:04 AM
$IMDX keep watch if this holds above 3.55
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Apr. 14 at 5:57 PM
$IMDX 7.11 gap fill is a 2x from here. Analyst pt is 12 but fair value is 8.33$
0 · Reply
Latest News on IMDX
iMDx Announces $26.0 Million Registered Direct Offering

Feb 11, 2026, 8:00 AM EST - 2 months ago

iMDx Announces $26.0 Million Registered Direct Offering


Oncocyte Reports Q1 2025 Results and Business Progress

May 12, 2025, 4:05 PM EDT - 1 year ago

Oncocyte Reports Q1 2025 Results and Business Progress


Oncocyte Provides Positive Update on Clinical Trial Progress

Apr 30, 2025, 8:30 AM EDT - 1 year ago

Oncocyte Provides Positive Update on Clinical Trial Progress


Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Jan 6, 2025, 4:05 PM EST - 1 year ago

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney


Oncocyte Reports First Quarter 2024 Financial Results

May 15, 2024, 4:05 PM EDT - 2 years ago

Oncocyte Reports First Quarter 2024 Financial Results


Oncocyte Reports Full Year 2023 Financial Results

Apr 12, 2024, 6:00 AM EDT - 2 years ago

Oncocyte Reports Full Year 2023 Financial Results


Oncocyte Announces 1-For-20 Reverse Stock Split

Jul 24, 2023, 1:35 PM EDT - 2 years ago

Oncocyte Announces 1-For-20 Reverse Stock Split


Oncocyte Begins Manufacturing Transplant Blood Test

Jun 27, 2023, 8:30 AM EDT - 3 years ago

Oncocyte Begins Manufacturing Transplant Blood Test


Oncocyte Reports First Quarter 2023 Financial Results

May 11, 2023, 8:00 AM EDT - 3 years ago

Oncocyte Reports First Quarter 2023 Financial Results


Oncocyte To Announce First Quarter 2023 Financial Results

Apr 27, 2023, 4:59 PM EDT - 3 years ago

Oncocyte To Announce First Quarter 2023 Financial Results


Oncocyte Presents New Data at AACR

Apr 18, 2023, 8:45 AM EDT - 3 years ago

Oncocyte Presents New Data at AACR


Oncocyte Announces Reduction in Force

Apr 12, 2023, 4:15 PM EDT - 3 years ago

Oncocyte Announces Reduction in Force


JohnPDaly
JohnPDaly Apr. 21 at 11:43 AM
0 · Reply
JohnPDaly
JohnPDaly Apr. 21 at 11:14 AM
$IMDX Daddy is home.
0 · Reply
SocioCobb
SocioCobb Apr. 21 at 4:54 AM
0 · Reply
JohnPDaly
JohnPDaly Apr. 21 at 2:28 AM
SEC-Outline $IMDX https://otp.tools.investis.com/clients/us/oncocyte/SEC/sec-outline.aspx?FilingId=19354433&Cik=0001642380&PaperOnly=0&HasOriginal=1
0 · Reply
jackedmund99
jackedmund99 Apr. 20 at 11:49 PM
$IMDX Neil Bradshaw, and Broadwood partners just bought more stock
0 · Reply
VaporWaves
VaporWaves Apr. 20 at 1:35 AM
$IMDX FDA Submission: On March 26, 2026, the company officially submitted GraftAssureDx for FDA review. This is an in-vitro diagnostic (IVD) test kit designed to monitor kidney transplant rejection using donor-derived cell-free DNA
0 · Reply
jackedmund99
jackedmund99 Apr. 17 at 3:25 PM
$IMDX create a weakness in the Stock so they can steal more shares cause they know what’s about to happen. The Stock is getting ready to be a teenager. It’s gonna have huge sales and there’s no real competition right now. I’m buying —thank you
1 · Reply
Bogwood
Bogwood Apr. 15 at 9:36 PM
$IMDX writing's on the wall that GraftAssure works from $CDNA's corp dev update today. Again, CareDx, EuroBio, Eurofins, TMO/Devyser and Natera are all checkmated because NGS takes too long to process even if performed in-house. The only competitors that could compete in theory would be Werfen/Omixon, but they aren't even close to setting up their FDA trial
1 · Reply
StockScanners
StockScanners Apr. 15 at 3:04 AM
$IMDX keep watch if this holds above 3.55
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Apr. 14 at 5:57 PM
$IMDX 7.11 gap fill is a 2x from here. Analyst pt is 12 but fair value is 8.33$
0 · Reply
SerpentHalo
SerpentHalo Apr. 14 at 5:25 PM
}Check out @SqueezeSharkie he’s been on absolute FIRE lately🔥 Drop him a follow, doesn’t cost you anything but a click🌟 $HUBC $RETO $IMDX $XNDU <<< on watch
0 · Reply
CaliberPalaceTrades
CaliberPalaceTrades Apr. 14 at 4:16 PM
If you like jumping in to them runners before they breakout... I would recommend Following that @ElevenXProfits guy below, Great trader, He's been on point with his entries 💯🔥 Decent momentum on $IMDX $TVTX $HOTH $HUBC today
0 · Reply
JohnPDaly
JohnPDaly Apr. 14 at 3:40 PM
$IMDX :-)
0 · Reply
jackedmund99
jackedmund99 Apr. 14 at 2:12 PM
$IMDX stock should be over eight dollars now - being manipulated by those who know it’s heading much higher so they can steal cheap stock
0 · Reply
JohnPDaly
JohnPDaly Apr. 14 at 12:10 PM
Real-World Evidence and Industry Momentum Builds for iMDx’s Flagship GraftAssure Assay – Insight Molecular Diagnostics Inc. $IMDX https://investors.imdxinc.com/news-releases/2026/04-14-2026-130523266
0 · Reply
Bogwood
Bogwood Apr. 13 at 5:07 PM
$IMDX Luciano's presentation that was quoted on the earnings call was posted finally. Highlights just how quick this switch can be from Prospera/AlloSure: https://www.youtube.com/watch?v=tlGQxLPlhoc
0 · Reply
jackedmund99
jackedmund99 Apr. 10 at 7:01 PM
$IMDX thanks for the 3300 I bought at avg cost 2.675
1 · Reply
NY2CHI
NY2CHI Apr. 10 at 5:43 PM
$IMDX added with some size here today. Management gets it, based on their Conference call. They've been institutionalizing their cap table in advance of FDA approval. Once approved, this will move.
0 · Reply
Logic102
Logic102 Apr. 8 at 8:42 PM
$IMDX The stock has over 50% Institutional Ownership with one approved product and another on the way. Please help me understand the current share price movement. I understand that it all comes down to sales in the end, but this drop is surprising.
1 · Reply
Logic102
Logic102 Apr. 8 at 7:01 PM
$IMDX bought more shares below $3. Strange day. Super Volatility.
0 · Reply
Logic102
Logic102 Apr. 8 at 3:08 PM
$IMDX Those who bought yesterday clearly had Insight!
0 · Reply
Logic102
Logic102 Apr. 7 at 9:08 PM
$IMDX I specialize in Asymmetric Risk/Reward situations of what I consider highly undervalued share prices with far more upside than downside. For what it's worth, I bought my first 700 shares today. Small position as I do more DD but like what I see thus far. I have another non-invasive diagnostic company small position in $BIAF which is even more beaten down, but not as financially stable as IMDX. They have what I call the Cologuard of Lung Cancer and their sales have been ramping nicely. Non-invasive, accurate tests with low false positives for unmet needs have a bright future IMO.
0 · Reply